Anti-cancer effect of tectochrysin in NSCLC cells through overexpression of death receptor and inactivation of STAT3

Cancer Letters

Volumn 353, Issue 1, 2014, Pages 95-103

  Oh, Saet Byul ^a   Hwang, Chul Ju ^a   Song, Suk Young ^a   Jung, Yu Yeon ^a   Yun, Hyung Mun ^a   Sok, Chang Hyun ^a   Sung, Ha Chang ^a   Yi, Jin Mu ^a   Park, Dong Hyun ^a   Ham, Young Wan ^b   Han, Sang Bae ^a   Hwang, Bang Yeon ^a   Hong, Jin Tae ^a  

^a Chungbuk National University   (South Korea)

^b Brigham Young University   (United States)

Author keywords

Death receptor; Lung cancer; STAT3; Tectochrysin

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR 3; FAS ANTIGEN; PROTEIN BAX; PROTEIN BCL 2; SMALL INTERFERING RNA; STAT3 PROTEIN; TECTOCHRYSIN; ANTINEOPLASTIC AGENT; DEATH RECEPTOR; DNA; FAS PROTEIN, HUMAN; FLAVONOID; STAT3 PROTEIN, HUMAN; TNFRSF25 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME MODIFICATION; HUMAN; HUMAN CELL; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROTEIN DNA BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; BINDING SITE; CELL PROLIFERATION; DOSE RESPONSE; GENETIC TRANSFECTION; GENETICS; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METABOLISM; MOLECULAR DOCKING; PATHOLOGY; PHOSPHORYLATION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE; UPREGULATION;

DEATH RECEPTOR; LUNG CANCER; STAT3; TECTOCHRYSIN;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BINDING SITES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; FLAVONOIDS; HUMANS; LUNG NEOPLASMS; MOLECULAR DOCKING SIMULATION; PHOSPHORYLATION; RECEPTORS, TUMOR NECROSIS FACTOR, MEMBER 25; RNA INTERFERENCE; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TRANSFECTION; UP-REGULATION;

EID: 84908364632     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.07.007     Document Type: Article

References (57)

1. Zandberga E., Kozirovskis V., Abols A., Andrejeva D., Purkalne G., Line A. Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. Genes Chromosom. Cancer 2013, 52:356-369.
2. Youn H., Jeong J.C., Jeong Y.S., Kim E.J., Um S.J. Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol. Pharm. Bull. 2013, 36:944-951.
3. Liao Z., Lin S.H., Cox J.D. Status of particle therapy for lung cancer. Acta Oncol. 2011, 50:745-756.
4. Pan M.H., Ho C.T. Chemopreventive effects of natural dietary compounds on cancer development. Chem. Soc. Rev. 2008, 37:2558-2574.
5. Bhardwaj A., Aggarwal B.B. Receptor-mediated choreography of life and death. J. Clin. Immunol. 2003, 23:317-332.
6. Park J., Lee J., Kang W., Chang S., Shin E.C., Choi C. TGF-beta1 and hypoxia-dependent expression of MKP-1 leads tumor resistance to death receptor-mediated cell death. Cell Death Dis. 2013, 4:e521.
7. Jo M., Park M.H., Kollipara P.S., An B.J., Song H.S., Han S.B., Kim J.H., Song M.J., Hong J.T. Anti-cancer effect of bee venom toxin and melittin in ovarian cancer cells through induction of death receptors and inhibition of JAK2/STAT3 pathway. Toxicol. Appl. Pharmacol. 2012, 258:72-81.
8. Singh A., Ni J., Aggarwal B.B. Death domain receptors and their role in cell demise. J. Interferon Cytokine Res.: Off. J. Int. Soc. Interferon Cytokine Res. 1998, 18:439-450.
9. Elrod H.A., Sun S.Y. Modulation of death receptors by cancer therapeutic agents. Cancer Biol. Ther. 2008, 7:163-173.
10. Yang L., Su L., Cao C., Xu L., Zhong D., Liu X. The chalcone 2'-hydroxy-4',5'-dimethoxychalcone activates death receptor 5 pathway and leads to apoptosis in human nonsmall cell lung cancer cells. IUBMB Life 2013, 65:533-543.
11. Kollipara P.S., Jeong H.S., Han S.B., Hong J.T. (E)-2,4-bis(p-hydroxyphenyl)-2-butenal has an antiproliferative effect on NSCLC cells induced by p38 MAPK-mediated suppression of NF-kappaB and up-regulation of TNFRSF10B (DR5). Br. J. Pharmacol. 2013, 168:1471-1484.
12. Fulda S., Debatin K.M. Exploiting death receptor signaling pathways for tumor therapy. Biochim. Biophys. Acta 2004, 1705:27-41.
13. Wu W.Y., Li J., Wu Z.S., Zhang C.L., Meng X.L. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer 2011, 11:506.
14. Kim H.G., Hwang Y.P., Jeong H.G. Kahweol blocks STAT3 phosphorylation and induces apoptosis in human lung adenocarcinoma A549 cells. Toxicol. Lett. 2009, 187:28-34.
15. Subramaniam A., Shanmugam M.K., Perumal E., Li F., Nachiyappan A., Dai X., Swamy S.N., Ahn K.S., Kumar A.P., Tan B.K., Hui K.M., Sethi G. Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. Biochim. Biophys. Acta 1835, 2013:46-60.
16. Zhang J., Wang S., Li Y., Xu P., Chen F., Tan Y., Duan J. Anti-diarrheal constituents of Alpinia oxyphylla. Fitoterapia 2013, 89:149-156.
17. Johnson D.E. Targeting proliferation and survival pathways in head and neck cancer for therapeutic benefit. Chin. J. Cancer 2012, 31:319-326.
18. Kim D.J., Chan K.S., Sano S., Digiovanni J. Signal transducer and activator of transcription 3 (Stat3) in epithelial carcinogenesis. Mol. Carcinog. 2007, 46:725-731.
19. Chen X., Du Y., Nan J., Zhang X., Qin X., Wang Y., Hou J., Wang Q., Yang J. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells. PLoS One 2013, 8:e63697.
20. Yang C.L., Liu Y.Y., Ma Y.G., Xue Y.X., Liu D.G., Ren Y., Liu X.B., Li Y., Li Z. Curcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia through Janus kinase-STAT3 signalling pathway. PLoS One 2012, 7:e37960.
21. Wang X., Crowe P.J., Goldstein D., Yang J.L. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int. J. Oncol. 2012, 41:1181-1191.
22. Boutabet K., Kebsa W., Alyane M., Lahouel M. Polyphenolic fraction of Algerian propolis protects rat kidney against acute oxidative stress induced by doxorubicin. Indian J. Nephrol. 2011, 21:101-106.
23. Surh Y. Molecular mechanisms of chemopreventive effects of selected dietary and medicinal phenolic substances. Mutat. Res. 1999, 428:305-327.
24. Das S., Das J., Samadder A., Boujedaini N., Khuda-Bukhsh A.R. Apigenin-induced apoptosis in A375 and A549 cells through selective action and dysfunction of mitochondria. Exp. Biol. Med. 2012, 237:1433-1448.
25. Wei L., Dai Q., Zhou Y., Zou M., Li Z., Lu N., Guo Q. Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: c-Src and hexokinase II. Biochim. Biophys. Acta 1830, 2013:3835-3845.
26. Flynn D.L., Rafferty M.F., Boctor A.M. Inhibition of 5-hydroxy-eicosatetraenoic acid (5-HETE) formation in intact human neutrophils by naturally-occurring diarylheptanoids: inhibitory activities of curcuminoids and yakuchinones. Prostaglandins, Leukotrienes, Med. 1986, 22:357-360.
27. Kiuchi F., Iwakami S., Shibuya M., Hanaoka F., Sankawa U. Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chem. Pharm. Bull. 1992, 40:387-391.
28. Chun K.S., Sohn Y., Kim H.S., Kim O.H., Park K.K., Lee J.M., Moon A., Lee S.S., Surh Y.J. Anti-tumor promoting potential of naturally occurring diarylheptanoids structurally related to curcumin. Mutat. Res. 1999, 428:49-57.
29. Park Y., Moon B.H., Yang H., Lee Y., Lee E., Lim Y. Complete assignments of NMR data of 13 hydroxymethoxyflavones. Mag. Reson. Chem.: MRC 2007, 45:1072-1075.
30. Trott O., Olson A.J. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010, 31:455-461.
31. Ren Z., Mao X., Mertens C., Krishnaraj R., Qin J., Mandal P.K., Romanowski M.J., McMurray J.S., Chen X. Crystal structure of unphosphorylated STAT3 core fragment. Biochem. Biophys. Res. Commun. 2008, 374:1-5.
32. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 2006, 58:621-681.
33. Gupta S.C., Phromnoi K., Aggarwal B.B. Morin inhibits STAT3 tyrosine 705 phosphorylation in tumor cells through activation of protein tyrosine phosphatase SHP1. Biochem. Pharmacol. 2013, 85:898-912.
34. Hsu Y.L., Kuo P.L., Chiang L.C., Lin C.C. Isoliquiritigenin inhibits the proliferation and induces the apoptosis of human non-small cell lung cancer a549 cells. Clin. Exp. Pharmacol. Physiol. 2004, 31:414-418.
35. Hsu Y.L., Kuo P.L., Liu C.F., Lin C.C. Acacetin-induced cell cycle arrest and apoptosis in human non-small cell lung cancer A549 cells. Cancer Lett. 2004, 212:53-60.
36. Tang S.Y., Zhong M.Z., Yuan G.J., Hou S.P., Yin L.L., Jiang H., Yu Z. Casticin, a flavonoid, potentiates TRAIL-induced apoptosis through modulation of anti-apoptotic proteins and death receptor 5 in colon cancer cells. Oncol. Rep. 2013, 29:474-480.
37. Murtaza I., Adhami V.M., Hafeez B.B., Saleem M., Mukhtar H. Fisetin, a natural flavonoid, targets chemoresistant human pancreatic cancer AsPC-1 cells through DR3-mediated inhibition of NF-kappaB, International journal of cancer. J. Int. Cancer 2009, 125:2465-2473.
38. Xie Z.H., Quan M.F., Liu F., Cao J.G., Zhang J.S. 5-Allyl-7-gen-difluoromethoxychrysin enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells. BMC Cancer 2011, 11:322.
39. Jin C.Y., Park C., Hwang H.J., Kim G.Y., Choi B.T., Kim W.J., Choi Y.H. Naringenin up-regulates the expression of death receptor 5 and enhances TRAIL-induced apoptosis in human lung cancer A549 cells. Mol. Nutr. Food Res. 2011, 55:300-309.
40. Mahmood Z., Shukla Y. Death receptors: targets for cancer therapy. Exp. Cell Res. 2010, 316:887-899.
41. Wen X., Lin Z.Q., Liu B., Wei Y.Q. Caspase-mediated programmed cell death pathways as potential therapeutic targets in cancer. Cell Prolif. 2012, 45:217-224.
42. Chen Y.F., Yang J.S., Chang W.S., Tsai S.C., Peng S.F., Zhou Y.R. Houttuynia cordata Thunb extract modulates G0/G1 arrest and Fas/CD95-mediated death receptor apoptotic cell death in human lung cancer A549 cells. J. Biomed. Sci. 2013, 20:18.
43. Zhang H.P., Takayama K., Su B., Jiao X.D., Li R., Wang J.J. Effect of sunitinib combined with ionizing radiation on endothelial cells. J. Radiat. Res. 2011, 52:1-8.
44. Parajuli B., Shin S.J., Kwon S.H., Cha S.D., Lee H.G., Bae I., Cho C.H. The synergistic apoptotic interaction of indole-3-carbinol and genistein with TRAIL on endometrial cancer cells. J. Korean Med. Sci. 2013, 28:527-533.
45. Oishi M., Iizumi Y., Taniguchi T., Goi W., Miki T., Sakai T. Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2. PLoS One 2013, 8:e55922.
46. Chen W., Wang X., Zhuang J., Zhang L., Lin Y. Induction of death receptor 5 and suppression of survivin contribute to sensitization of TRAIL-induced cytotoxicity by quercetin in non-small cell lung cancer cells. Carcinogenesis 2007, 28:2114-2121.
47. Yan J., Wang Q., Zheng X., Sun H., Zhou Y., Li D., Lin Y., Wang X. Luteolin enhances TNF-related apoptosis-inducing ligand's anticancer activity in a lung cancer xenograft mouse model. Biochem. Biophys. Res. Commun. 2012, 417:842-846.
48. Li B., Ren H., Yue P., Chen M., Khuri F.R., Sun S.Y. The novel Akt inhibitor API-1 induces c-FLIP degradation and synergizes with TRAIL to augment apoptosis independent of Akt inhibition. Cancer Prev. Res. (Phila) 2012, 5:612-620.
49. Lin Y.D., Chen S., Yue P., Zou W., Benbrook D.M., Liu S., Le T.C., Berlin K.D., Khuri F.R., Sun S.Y. CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells. Cancer Res. 2008, 68:5335-5344.
50. Lin L., Deangelis S., Foust E., Fuchs J., Li C., Li P.K., Schwartz E.B., Lesinski G.B., Benson D., Lu J., Hoyt D., Lin J. A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells. Mol. Cancer 2010, 9:217.
51. Huang S., Chen M., Shen Y., Shen W., Guo H., Gao Q., Zou X. Inhibition of activated Stat3 reverses drug resistance to chemotherapeutic agents in gastric cancer cells. Cancer Lett. 2012, 315:198-205.
52. Yin Z., Zhang Y., Li Y., Lv T., Liu J., Wang X. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells. Acta Histochem. 2012, 114:151-158.
53. Chiu H.C., Chou D.L., Huang C.T., Lin W.H., Lien T.W., Yen K.J., Hsu J.T. Suppression of Stat3 activity sensitizes gefitinib-resistant non small cell lung cancer cells. Biochem. Pharmacol. 2011, 81:1263-1270.
54. Lirdprapamongkol K., Sakurai H., Abdelhamed S., Yokoyama S., Athikomkulchai S., Viriyaroj A., Awale S., Ruchirawat S., Svasti J., Saiki I. Chrysin overcomes TRAIL resistance of cancer cells through Mcl-1 downregulation by inhibiting STAT3 phosphorylation. Int. J. Oncol. 2013, 43:329-337.
55. Seo H.S., Choi H.S., Kim S.R., Choi Y.K., Woo S.M., Shin I., Woo J.K., Park S.Y., Shin Y.C., Ko S.G. Apigenin induces apoptosis via extrinsic pathway, inducing p53 and inhibiting STAT3 and NFkappaB signaling in HER2-overexpressing breast cancer cells. Mol. Cell. Biochem. 2012, 366:319-334.
56. Chittezhath M., Deep G., Singh R.P., Agarwal C., Agarwal R. Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells. Mol. Cancer Ther. 2008, 7:1817-1826.
57. Prakobwong S., Gupta S.C., Kim J.H., Sung B., Pinlaor P., Hiraku Y., Wongkham S., Sripa B., Pinlaor S., Aggarwal B.B. Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis 2011, 32:1372-1380.